

HPAP -064- Donor Summary



HPAP	-064	UNOS	
Recovery OPO	TXSB –Texas Southwest Transplant Alliance	Allocation Via	UPENN <input type="checkbox"/> nPOD <input checked="" type="checkbox"/>
Age (years)	24	DCD	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
Race	Black or African American	DBD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
Sex	M <input checked="" type="checkbox"/> F <input type="checkbox"/>	Admission to Cross Clamp	158 Hours 34 .Mins.
ABO (Rh)	B+	Cross Clamp Time	07/14/2020 01:57
BMI (Kg/m²)	16.980	Cold Ischemia Time*	17 Hours 53 Mins.
Weight (kg)	52		
Height (cm)	175		
Cause of Death	Anoxia	Preservation Solution	UW <input checked="" type="checkbox"/> HTK <input type="checkbox"/>
Mechanism of Injury	Anoxia	Organs Recovered	Heart <input type="checkbox"/> Kidney <input checked="" type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input checked="" type="checkbox"/> Liver <input checked="" type="checkbox"/> Intestine <input type="checkbox"/>
Cardiac Arrest/Downtime	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:	<input type="text"/> Hours <input type="text"/> Mins. Not Available
CPR / Time	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Organs Discarded	Heart <input type="checkbox"/> Kidney <input type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input type="checkbox"/> Liver <input type="checkbox"/> Intestine <input type="checkbox"/>
Total Est. Downtime	No down time	Blood Culture	No Growth
Date /Time of Admission	07/07/2020 11:23 MDT	PHS High Risk	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
		Acute Lung Injury	Airspace disease in the right lower lobe

*Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.

HPAP -064- Donor Summary



Medical History:

		Duration	Medications	Compliance
Type of Diabetes	T1D	Unknown-diagnosed in the current admission	----	----
History of cancer	----	----	----	----
CAD	----	----	----	----
Hypertension	----	----	----	----
Hyperlipidemia	----	----	----	----
Autoimmune disease	----	----	----	----
Family History	CAD <input checked="" type="checkbox"/>	Diabetes <input checked="" type="checkbox"/>	Auto immune disease <input type="checkbox"/>	Others:
Surgical History:	----			
Comments:	Maternal grandmother's sister had diabetes Maternal grandfather had CAD Smoked Marijuana daily since age 16			

Hemodynamic Profile

Average BP During Hospitalization (mmHg)	119/70	
Average Low BP During Hospitalization	87/49	Duration: 15 Minutes
Average BP in OR (mmHg)	121/69	
Average Low BP in OR (mmHg)	104/70	Duration: 10 Minutes
Average HR in OR (bpm)	91	
ABG-pH range	7.04 – 7.46	

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	----	----	----
PRBCs	----	2	642
Platelets	----	1	245
Norepinephrine (Levophed)	----	13 MCG/Min started 7 days before the organ recovery for the duration of 111:30 hrs	
Vasopressin	----	----	----
Neo-Syneprine	----	----	----
Epinephrine	----	----	----
Phenylephrine	----	----	----
Dopamine	----	1 MCG/Min started 3 days before the organ recovery for the duration of 8:00 hrs	

HPAP -064- Donor Summary



HPAP -064- Donor Summary



Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	---	---	---
PRBCs	---	---	---
Platelets	---	---	---
Norepinephrine (Levophed)	---	---	---
Vasopressin	---	---	---
Neo-Syneprine (phenylephrine)	---	---	---
Epinephrine	---	---	---
Dopamine	---	---	---
Heparin	---	50,000	---

Initial Autoantibody Screening (nPOD): ELISA

GAD-65	IA-2
Negative	Negative

Confirmatory results: Radioimmuno Assay (RIA)

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)
Results	0	0	- 0.002	0.027
Cut-off values	20	5	0.01	0.02

*Sample obtained at time of organ recovery.

	C-peptide (ng/ml)	Proinsulin
Results	0.25	ND

*Sample obtained at time of organ recovery.

HLA (OPO)*

Class 1	A	2	34	Class II	DR	1	17
	B	58	75		DR51	N-Negative	N-Negative
	C	06	16		DR52	52	-
	Bw4	Positive			DR53	N-Negative	N-Negative
	Bw6	Positive			DQB1	2	5
					DQA1	01	05
					DPB1	01:01	18:01
Comment:							

HPAP -064- Donor Summary



Confirmatory HLA (UPENN)*

Class 1	A	02:01	34:02	Class II	DRB1	03:01	01:02
	B	15:31	58:02		DRB3	02:02	-
	C	06:02	16:01		DRB4	-	-
					DRB5	-	-
					DQB1	02:01	05:01
					DQA1	01:01	05:01
					DPB1	01:01	18:01
					DPA1	01:03	02:01

*HLA typing performed using NGS

Infectious Disease Serology

Test	Result	Hemo/Plasma Dilution Status	
		Qualified	Non-Qualified
EBV IgG	Positive	✓	-
EBV IgM	Negative	✓	-
CMV	Non- Reactive	✓	-
HBcAb	Non- Reactive	✓	-
HBsAg	Non- Reactive	✓	-
HCV Ab	Non- Reactive	✓	-
HIV I/II	Non- Reactive	✓	-
Syphilis	Non- Reactive	✓	-
Procleix Ultrio	Non- Reactive	✓	-
Ultrio HBV (HBV NAT)	Negative	✓	-
Ultrio HCV (HCV NAT)	Negative	✓	-
Ultrio HIV (HIV NAT)	Negative	✓	-
Toxoplasma Ab	Negative	✓	-
WNV NAT	Non- Reactive	✓	-
SARS-CoV-2	Negative	✓	-



HPAP -064- Donor Summary

Laboratory Panel

	Initial	Peak	Terminal
Na (mEq/L) (135-145)	137	164	157
Creatinine (<1.5)	5.7	4.9	4.5
Glucose (mg/dL) (60-150)	1149	1149	240
HbA1C%	13 (9.7)	-	-
Total bilirubin (0-1.0)	0.8	2	1.5
SGOT (AST) (0-40)	48	1374	262
SGPT (ALT) (5-35)	36	441	144
Alkaline phosphatase (45-110)	103	316	200
Serum Amylase (23-851)	32	-	-
Serum Lipase (0-80)	1334	1334	73
WBC (THO/uL) (4.5-11.0)	6.8	12.23	11.9
Hgb (g/dL) (12-16)	14.4	14.4	9
Platelets (THO/uL) (150-350)	195	195	82
INR (<2.0)	2	2.1	1.5

Urinalysis

	1 st	2 nd	3 rd	4 th
Glucose	Positive (>= 500)	Negative	Positive (50)	Negative

Medications During Hospitalization

Steroids**	Yes	2 gm Solumedrol
Diuretics	Yes	20-40 mg Lasix
T3 Protocol	----	
T4 Protocol*	Yes	
Insulin**	Yes	
Antihypertensive	----	
Vasodilators	----	
DDAVP**	----	
Total parenteral nutrition	----	
Other	----	Specify

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015;7 17-27.

** Excluding T4 Protocol